Last reviewed · How we verify
Verluma (technetium (99mTc) nofetumomab merpentan)
Verluma (generic name: technetium (99mTc) nofetumomab merpentan) is a drug developed by Boehringer Ingelheim. It is currently FDA-approved (first approved 1996) for Nuclear medicine imaging procedure.
Verluma is a diagnostic agent used in the diagnosis of various types of cancer, including lung, gastrointestinal, breast, ovary, pancreas, kidney, cervix, and bladder carcinoma. It is a technetium-99m (99mTc) labeled antibody derivative, specifically a mouse monoclonal antibody derivative attached to the chelator merpentan.
At a glance
| Generic name | technetium (99mTc) nofetumomab merpentan |
|---|---|
| Sponsor | Boehringer Ingelheim |
| Therapeutic area | Other |
| Phase | FDA-approved |
| First approval | 1996 |
Approved indications
- Nuclear medicine imaging procedure
Common side effects
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Verluma CI brief — competitive landscape report
- Verluma updates RSS · CI watch RSS
- Boehringer Ingelheim portfolio CI
Frequently asked questions about Verluma
What is Verluma?
What is Verluma used for?
Who makes Verluma?
What is the generic name of Verluma?
When was Verluma approved?
What development phase is Verluma in?
Related
- Manufacturer: Boehringer Ingelheim — full pipeline
- Therapeutic area: All drugs in Other
- Indication: Drugs for Nuclear medicine imaging procedure
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing